Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Non-Hodgkin 7Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Renal Insufficiency 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Hepatic Insufficiency 1HER2 Positive Breast Cancer 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1

Interventions

Gemcitabine 34Cisplatin 21Capecitabine 18Oxaliplatin 15Leucovorin 10Fluorouracil 10Irinotecan 8Erlotinib Hydrochloride 7pembrolizumab 5Bevacizumab 5Radiotherapy 4Carboplatin 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Watchful Waiting 3Taxes 3Sorafenib 3Platinum 3Interleukin-12 Subunit p35 3Immunohistochemistry 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3trifluridine tipiracil drug combination 2tremelimumab 2regorafenib 2durvalumab 2dehydroftorafur 2Trastuzumab 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gallbladder Neoplasms × copanlisib × Clear all
NCT02631590 2021-08-04

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
24 enrolled 11 charts
Gastrointestinal

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡